Diagnostic methods for peritoneal molecular residual disease in gastric cancer.
10.3760/cma.j.cn441530-20230117-00016
- Author:
Tong Bo WANG
1
;
Zheng LI
1
;
Dong Bing ZHAO
1
Author Information
1. Department of Pancreatic and Gastric Surgery, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Stomach Neoplasms/pathology*;
Peritoneal Neoplasms/secondary*;
Liquid Biopsy;
Neoplasm, Residual/genetics*
- From:
Chinese Journal of Gastrointestinal Surgery
2023;26(5):419-422
- CountryChina
- Language:Chinese
-
Abstract:
Peritoneal metastasis of gastric cancer serving as the most frequent form of metastasis, is one of the leading causes of death. A portion of surgically treated patients often suffer from small peritoneal residual metastasis, which will lead to recurrence and metastasis of gastric cancer patients after surgery. Given these, the prevention and treatment of peritoneal metastasis of gastric cancer deserves more attention. Molecular residual disease (MRD) refers to the molecular abnormalities of tumor origin that cannot be found by traditional imaging or other laboratory methods after treatment, but can be found by liquid biopsy, representing the possibility of tumor persistence or clinical progress. In recent years, the detection of MRD based on ctDNA has gradually become a research hotspot in the prevention and treatment of peritoneal metastasis. Our team established a new method for MRD molecular diagnosis of gastric cancer, and reviewed the research achievements in this field.
